（记者 张明双） 每经AI快讯，有投资者在投资者互动平台提问：请问公司已经有一站式飞秒激光方案，是否能够提供 平均功率超过20KW的高重频固体激光方案？ 福晶科技（002222.SZ）12月21日在投资者互动平台表示，公司可以为客户提供飞秒等超快激光用的晶 体、光学、器件相关产品，具体适配机型需客户综合评估。 ...

证券代码：002222 证券简称：福晶科技 公告编号：2025-033 福建福晶科技股份有限公司 2025年前三季度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 福建福晶科技股份有限公司（以下简称"本公司"或"公司"）于2025年5月20日 召开的2024年度股东大会审议通过了《关于2025年中期分红安排的议案》，授权董事会 根据股东大会决议在符合利润分配的条件下制定并实施具体的中期分红方案。公司于 2025年10月28日召开第七届董事会第八次会议，审议通过了《2025年前三季度利润分配 方案》。现将本次权益分派事宜公告如下 一、股东大会及董事会审议通过利润分配方案等情况 本公司 2025 年前三季度权益分派方案为：以公司现有总股本 470,250,000 股为基 数，向全体股东每 10 股派 1.000000 元人民币现金（含税；扣税后，通过深股通持有股 份的香港市场投资者、境外机构（含 QFII、RQFII）以及持有首发前限售股的个人和证 券投资基金每 10 股派 0.900000 元；持有首发后限售股、股权激励限售股及无限售流通 股的 ...

本次权益分派股权登记日为：2025年12月24日，除权除息日为：2025年12月25日。 格隆汇12月17日丨福晶科技(002222.SZ)发布2025年前三季度权益分派实施公告，本公司2025年前三季 度权益分派方案为：以公司现有总股本4.70亿股为基数，向全体股东每10股分配现金股利人民币1.00元 （含税），共派发现金股利人民币4702.5万元（含税）。 ...

New Stock Issuance - Tian Su Measurement (证券代码: 301449) issued at a price of 36.80[1] - Xi Hua Technology (证券代码: 732248) issued at a price of 10.10[1] Tender Offer Periods - Tender offer for Quan Yin Gao Ke (证券代码: 300087) from December 4, 2025, to January 5, 2026[1] - Tender offer for Tian Pu Shares (证券代码: 605255) from November 20, 2025, to December 19, 2025[1] Trading Alerts - *ST Guang Dao (证券代码: 920680) has 13 trading days remaining until the last trading day[1] - *ST Su Wu (证券代码: 600200) has 11 trading days remaining until the last trading day[1] Abnormal Fluctuations - Sai Wei Electronics (证券代码: 300456) reported severe abnormal fluctuations[1] - Other stocks with abnormal fluctuations include *ST Li Fang (证券代码: 300344) and *ST Zheng Ping (证券代码: 603843)[1]

Group 1: Pharmaceutical Industry Insights - The 2026 pharmaceutical industry strategy report highlights a reversal in the market, driven by innovative drugs, with significant gains across various secondary sectors, particularly in Hong Kong where innovative drugs saw an increase of over 80% year-to-date [6][8] - Key catalysts for innovative drugs include policy support and successful business development (BD) transactions, with notable deals exceeding $1 billion validating the international competitiveness of Chinese innovative drugs [6][7] - A significant policy reform in October 2025 initiated a dual-track system for medical insurance, addressing the high-value innovative drugs' inclusion challenges, which is expected to guide commercial insurance to cover these gaps [6] Group 2: Company-Specific Updates - Yixin Group (2858.HK) has been included in the Hong Kong Stock Exchange Technology 100 Index, which is expected to enhance liquidity, and has renewed a strategic cooperation agreement for used car services, reflecting confidence in the growing demand for this segment [10][11] - The company reported a robust Q3 performance with a total of 235,000 auto financing transactions, a year-on-year increase of 22.6%, outperforming the market growth rate of approximately 11% [11] - Yixin Group's financial technology business has shown significant growth, with financing facilitated through its platform reaching approximately 114 billion yuan, a year-on-year increase of about 102% [11] Group 3: Electronic Sector Developments - Fuzhicheng Technology (002222.SZ) has exceeded revenue expectations, with a projected revenue growth to 11.15 billion yuan in 2025, and net profit expected to reach 3.02 billion yuan [15] - The company maintains a strong position in the ultra-precision optics sector, with its subsidiary achieving significant advancements and a revenue increase of 73.66% in H1 2025 [14] - Naxin Microelectronics (688052.SH) has successfully completed its H-share IPO, marking a critical step in its internationalization, with projected revenues of 33.01 billion yuan in 2025 [19]

（编辑 丛可心） 证券日报网讯 12月10日晚间，福晶科技发布公告称，公司股票连续三个交易日内（2025年12月8日、12 月9日、12月10日）收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动情形；经核查，公司前 期披露信息无需更正补充，经营环境未发生重大变化，控股股东物构所于异常波动期间减持104.29万 股。 ...

证券日报网讯12月10日晚间，福晶科技（002222）发布公告称，公司于近日收到控股股东物构所出具的 书面告知函及《简式权益变动报告书》，物构所于2025年12月1日至12月9日通过集中竞价交易减持275 万股，减持后持股比例由20.58%降至20.00%，触及5%整数倍。 ...

每经AI快讯，有投资者在投资者互动平台提问：请问公司是否有能力制造RMS≤0.1nm，PV≤1nm的超光 滑反射镜？ 福晶科技（002222.SZ）12月11日在投资者互动平台表示，尊敬的投资者，您好！公司目前最高光学加 工精度可以做到＜0.1nm RMS（平面光学元器件），谢谢！ （记者 曾健辉） ...

Investment Rating - The investment rating for the company is "Buy" [5]. Core Insights - The company maintains a solid position in its traditional business, with significant R&D investments yielding fruitful results. It is the largest global producer of LBO and BBO crystals and components, holding the number one market share globally. The precision optical products segment has achieved mass production of new prism gratings for high-speed optical network dynamic control modules, with performance metrics reaching international advanced levels, making it a key supplier for leading domestic and international companies [1][5]. - The company has targeted high-end laser device markets to address the bottleneck of imported core components, successfully breaking the monopoly of foreign suppliers with its self-developed acousto-optic and magneto-optic devices. In the first three quarters of 2025, the company achieved revenue of 842 million yuan, a year-on-year increase of 26.62%, and a net profit attributable to the parent company of 218 million yuan, up 29.75% year-on-year, with Q3 2025 marking record highs for both revenue and profit [1]. - The company’s subsidiary, Zhiqi Photonics, has made significant progress in the ultra-precision optical field, achieving a revenue of 49.05 million yuan in the first half of 2025, a year-on-year increase of 73.66%, and successfully turning a profit. The company is well-positioned to capitalize on future opportunities in ultra-precision optics [2][3]. Financial Projections - Revenue projections for the company are estimated at 1.115 billion yuan for 2025, 1.339 billion yuan for 2026, and 1.503 billion yuan for 2027, with corresponding net profits of 302 million yuan, 406 million yuan, and 494 million yuan respectively. The company is expected to see steady growth across its various business segments [3][4]. - The projected growth rates for revenue are 27.3% in 2025, 20.1% in 2026, and 12.2% in 2027, while net profit growth rates are expected to be 38.0% in 2025, 34.6% in 2026, and 21.6% in 2027 [4]. Key Data - The company’s earnings per share (EPS) is projected to be 0.64 yuan in 2025, 0.86 yuan in 2026, and 1.05 yuan in 2027. The price-to-earnings (P/E) ratio is expected to decrease from 99.9 in 2025 to 61.0 in 2027, indicating improving valuation metrics [4][10]. - The company’s return on equity (ROE) is projected to improve from 17.8% in 2025 to 20.8% in 2027, while the gross profit margin is expected to stabilize around 56.5% in 2025 and 56.7% in 2027 [10].

Group 1 - The company maintains a strong position in its traditional business, being the largest global producer of LBO and BBO crystals and components, with a market share of 1st globally [1] - In the precision optics sector, the company has achieved mass production of new prism gratings for dynamic control modules in high-speed optical networks, reaching international advanced performance levels [1] - The company has successfully developed self-researched acousto-optic and magneto-optic devices, breaking the monopoly of foreign suppliers in the laser device market [1] Group 2 - The subsidiary, Zhiqi Photon, focuses on ultra-precision optics, planning to develop and manufacture optical components for high-end applications in analysis instruments, detection equipment, and life sciences [2] - Zhiqi Photon reported revenue of 49.05 million yuan in H1 2025, a year-on-year increase of 73.66%, and achieved profitability, indicating positive future prospects in ultra-precision optics [2] - The company has extensive experience in the field of Yttrium Vanadate (YVO4) crystals, being one of the first to research and achieve mass production, positioning itself well in the OCS market [2] Group 3 - Revenue projections for the company are estimated at 1.115 billion yuan in 2025, 1.339 billion yuan in 2026, and 1.503 billion yuan in 2027, with net profits expected to be 302 million yuan, 406 million yuan, and 494 million yuan respectively [3] - The company is expected to see steady growth across its various business segments, with positive developments in ultra-precision optics from its subsidiary Zhiqi Photon [3]